Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 19/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3428843 | 0.90 | RYR2 (0.67) | RYR2 | |
| SCHEMBL806953 | 0.89 | RYR2 (0.63) | RYR2 | |
| SCHEMBL15705417 | 0.83 | RYR2 (0.43) | RYR2 | |
| SCHEMBL807117 | 0.81 | RYR2 (0.79) | RYR2 | |
| SCHEMBL6867447 | 0.81 | RYR2 (0.83) | RYR2 | |
| Surlorian SCHEMBL15326996 | 0.79 | RYR2 (0.58) | RYR2 | |
| Surlorian SCHEMBL29728244 | 0.79 | RYR2 (0.58) | RYR2 | |
| SCHEMBL13622141 | 0.79 | RYR2 (0.55) | RYR2 | |
| SCHEMBL12265307 | 0.79 | RYR2 (0.88) | RYR2 | |
| SCHEMBL806609 | 0.79 | RYR2 (1.00) | RYR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710045-B2 | Agents for preventing and treating disorders involving modulation of the ryanodine receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-04-29 | — | — | US | disclosed |
| US-20110172190-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172190-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | RYR1, RYR2, ATP2A1 | RYR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.